Gleb Filippov

1.3k total citations
27 papers, 650 citations indexed

About

Gleb Filippov is a scholar working on Experimental and Cognitive Psychology, Cognitive Neuroscience and Endocrine and Autonomic Systems. According to data from OpenAlex, Gleb Filippov has authored 27 papers receiving a total of 650 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Experimental and Cognitive Psychology, 18 papers in Cognitive Neuroscience and 5 papers in Endocrine and Autonomic Systems. Recurrent topics in Gleb Filippov's work include Sleep and related disorders (19 papers), Sleep and Wakefulness Research (18 papers) and Circadian rhythm and melatonin (5 papers). Gleb Filippov is often cited by papers focused on Sleep and related disorders (19 papers), Sleep and Wakefulness Research (18 papers) and Circadian rhythm and melatonin (5 papers). Gleb Filippov collaborates with scholars based in United States, United Kingdom and Japan. Gleb Filippov's co-authors include Margaret Moline, Gary Zammit, Carlos Perdomo, Kate Pinner, Naoki Kubota, Patricia Murphy, Shobha Dhadda, Russell Rosenberg, Jane Yardley and Mikko Kärppä and has published in prestigious journals such as Blood, Neurology and SLEEP.

In The Last Decade

Gleb Filippov

26 papers receiving 643 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gleb Filippov United States 11 484 458 291 72 66 27 650
Kerry Budd United States 5 482 1.0× 512 1.1× 347 1.2× 12 0.2× 30 0.5× 9 627
Corinne Staner France 11 301 0.6× 300 0.7× 194 0.7× 69 1.0× 34 0.5× 12 508
D. Alan Lankford United States 15 268 0.6× 303 0.7× 214 0.7× 21 0.3× 38 0.6× 19 527
Daniel Pardi United States 7 192 0.4× 244 0.5× 118 0.4× 31 0.4× 38 0.6× 8 436
Judith Laredo France 7 208 0.4× 138 0.3× 149 0.5× 66 0.9× 153 2.3× 12 523
Stephen N. Brooks United States 8 358 0.7× 423 0.9× 309 1.1× 56 0.8× 6 0.1× 14 589
Helen Slawik Germany 13 80 0.2× 82 0.2× 90 0.3× 49 0.7× 71 1.1× 15 325
Claudia Morabito Italy 6 230 0.5× 231 0.5× 291 1.0× 15 0.2× 5 0.1× 13 462
Erdal Işık Türkiye 8 80 0.2× 108 0.2× 37 0.1× 56 0.8× 30 0.5× 13 340
Deborah Matzura‐Wolfe United States 6 128 0.3× 121 0.3× 80 0.3× 52 0.7× 12 0.2× 8 364

Countries citing papers authored by Gleb Filippov

Since Specialization
Citations

This map shows the geographic impact of Gleb Filippov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gleb Filippov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gleb Filippov more than expected).

Fields of papers citing papers by Gleb Filippov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gleb Filippov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gleb Filippov. The network helps show where Gleb Filippov may publish in the future.

Co-authorship network of co-authors of Gleb Filippov

This figure shows the co-authorship network connecting the top 25 collaborators of Gleb Filippov. A scholar is included among the top collaborators of Gleb Filippov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gleb Filippov. Gleb Filippov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kulasekararaj, Austin, Morag Griffin, Caroline Piatek, et al.. (2024). Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH. Blood. 145(8). 811–822. 2 indexed citations
2.
3.
4.
Rosenberg, Russell, Margaret Moline, Jane Yardley, et al.. (2022). Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder. Postgraduate Medicine. 134(3). 316–325. 9 indexed citations
5.
Landry, Ishani, Nancy Hall, Jagadeesh Aluri, et al.. (2022). Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study. Journal of Psychopharmacology. 36(6). 745–755. 7 indexed citations
6.
Moline, Margaret, Stephen Thein, Mohammad Bsharat, et al.. (2021). Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial. The Journal of Prevention of Alzheimer s Disease. 8(1). 7–18. 31 indexed citations
7.
Cheng, Jocelyn Y., Margaret Moline, Gary Zammit, et al.. (2021). Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Clinical Drug Investigation. 41(5). 449–457. 5 indexed citations
8.
Landry, Ishani, Jagadeesh Aluri, Nancy Hall, et al.. (2021). Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females. Clinical Pharmacology in Drug Development. 10(9). 1089–1098. 1 indexed citations
9.
Yardley, Jane, Mikko Kärppä, Yuichi Inoue, et al.. (2021). Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Medicine. 80. 333–342. 53 indexed citations
10.
11.
Cheng, Jocelyn Y., Gleb Filippov, Margaret Moline, et al.. (2020). Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double‐blind, placebo‐controlled, crossover study. Journal of Sleep Research. 29(4). e13021–e13021. 31 indexed citations
12.
Thein, Stephen, et al.. (2019). F1‐06‐04: RESPONSE TO TREATMENT WITH LEMBOREXANT: SUBJECTS WITH IRREGULAR SLEEP‐WAKE RHYTHM DISORDER AND ALZHEIMER'S DISEASE DEMENTIA. Alzheimer s & Dementia. 15(7S_Part_3). 4 indexed citations
13.
Yardley, Jane, Mikko Kärppä, Yuichi Inoue, et al.. (2019). Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: 12-month results from sunrise-2. Sleep Medicine. 64. S263–S264. 3 indexed citations
14.
Rosenberg, Russell, et al.. (2019). SAFETY OF LEMBOREXANT IN ELDERLY SUBJECTS WITH INSOMNIA: RESULTS FROM A PHASE 3 STUDY (SUNRISE 1). American Journal of Geriatric Psychiatry. 27(3). S196–S197. 1 indexed citations
15.
Cheng, Jocelyn Y., Margaret Moline, Gleb Filippov, et al.. (2019). 0429 Respiratory Safety of Lemborexant in Adult and Elderly Subjects with Mild Obstructive Sleep Apnea. SLEEP. 42(Supplement_1). A173–A174. 2 indexed citations
16.
Rosenberg, Russell, Patricia Murphy, Gary Zammit, et al.. (2019). Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder. JAMA Network Open. 2(12). e1918254–e1918254. 159 indexed citations
17.
Kärppä, Mikko, Margaret Moline, Jane Yardley, et al.. (2019). 0367 Lemborexant Treatment for Insomnia: 6-month Safety. SLEEP. 42(Supplement_1). A149–A150. 2 indexed citations
18.
Vermeeren, Annemiek, Stefan Jongen, Patricia Murphy, et al.. (2018). On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. SLEEP. 42(4). 54 indexed citations
19.
Wang, Gang, Mette Gislum, Gleb Filippov, & Stuart Montgomery. (2015). Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Current Medical Research and Opinion. 31(4). 785–794. 45 indexed citations
20.
Eliseev, Roman A., et al.. (2006). Role of cyclophilin D in the resistance of brain mitochondria to the permeability transition. Neurobiology of Aging. 28(10). 1532–1542. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kerry Budd Breakdown of academic impact, for papers by Corinne Staner Breakdown of academic impact, for papers by D. Alan Lankford Breakdown of academic impact, for papers by Daniel Pardi Breakdown of academic impact, for papers by Judith Laredo Breakdown of academic impact, for papers by Stephen N. Brooks Breakdown of academic impact, for papers by Helen Slawik Breakdown of academic impact, for papers by Claudia Morabito Breakdown of academic impact, for papers by Erdal Işık Breakdown of academic impact, for papers by Deborah Matzura‐Wolfe
Rankless by CCL
2026